Showing 3181-3190 of 3314 results for "".
- Exonate Closes £1.5 Million Fundraising Accelerate Development Eye Drop Treatment for Retinal Neovascular Diseaseshttps://modernod.com/news/exonate-closes-1-5-million-fundraising-accelerate-development-eye-drop-treatment-for-retinal-neovascular-diseases/2476222/Exonate announces the successful closing of its fourth financing round, raising £1.5 million. The funds raised will be used to accelerate the development of Exonate’s lead product, an eye drop for the treatment of retinal neovascular diseases. The company continues to make substantial progress an
- Focus Vision Supplements Launches Reformulated Version of Omega-3 Focus Relief Plushttps://modernod.com/news/focus-vision-supplements-launches-reformulated-version-of-omega-3-focus-relief-plus/2476228/Covalent Medical, a network of over 385 ophthalmologists who distribute vision supplements sold in practitioners’ offices in the United States under the brand name Focus Vision Supplements, is launching a reformulated version of their leading omega-3 formulation Focus Relief Plus. Focus Re
- George A. Williams, MD, Begins Term as 2019 President of the American Academy of Ophthalmologyhttps://modernod.com/news/george-a-williams-md-begins-term-as-2019-president-of-the-american-academy-of-ophthalmology/2476229/George A. Williams, MD, today begins his term as the 123rd president of the American Academy of Ophthalmology. Dr. Williams, a retina specialist, was elected by the Academy’s community of 32,000 ophthalmologists in recognition of his scientific leadership and his deep commitment to advocati
- Results RNA Issues Voluntary Worldwide Recall of Lubrisine Eye Drops Due to Manufacturing Sterility Concerns and Undeclared Colloidal Silverhttps://modernod.com/news/results-rna-issues-voluntary-worldwide-recall-of-lubrisine-eye-drops-due-to-manufacturing-sterility-concerns-and-undeclared-colloidal-silver/2476230/Results RNA is voluntarily recalling Lubrisine Eye Drops to the healthcare practitioner, retail or consumer level. This product, in a recent FDA inspection, was found to be manufactured using practices that do not support its sterility and contained undeclared colloidal silver.
- 2018 Best of Eyetubehttps://modernod.com/news/2018-best-of-eyetube/2476238/Cataract & Refractive Surgery Today (CRST) has compiled the best content of 2018 from Eyetube.net, the leading video resource for ophthalmologists. Below are descriptions of a few of the top videos. To view all of the videos and their descriptions, click
- AMD Monitoring Comes Home: The Promise of Innovative Remote Techhttps://modernod.com/news/amd-monitoring-comes-home-the-promise-of-innovative-remote-tech/2476239/Age-related macular degeneration (AMD) is the leading cause of severe vision loss in older Americans. AMD is a degenerative disease that affects the macula, or the central part of the retina, which has the highest density of photoreceptors, allowing for high-resolution central visual acuity. An e
- Carl Zeiss Meditec Completes Acquisition of IanTECHhttps://modernod.com/news/carl-zeiss-meditec-completes-acquisition-of-iantech/2476242/Carl Zeiss Meditec has officially completed its acquisition of IanTECH, a privately held company focused on technology solutions for micro-interventional cataract surgery headquartered in Reno, Nevada. IanTECH is the maker of the miLOOP Lens Fragmentation Device, which is the first in a li
- First IC-8 Small Aperture IOL Implanted in the United Stateshttps://modernod.com/news/first-ic-8-small-aperture-iol-implanted-in-the-united-states/2476252/AcuFocus announced that the first US patient has been implanted with the IC-8 small aperture IOL as part of its pivotal study of the IC-8 lens in cataract patients. The company recently announced approval for an investigational device exemption (IDE) from the FDA to conduct the study. The
- Criminal Case Against James Mazzo Dismissedhttps://modernod.com/news/criminal-case-against-james-mazzo-dismissed/2476151/After a legal battle that spanned a decade, the insider trading criminal case against ophthalmic executive James Mazzo has come to an end. Late Thursday at the Ronald Reagan Federal Building in Santa Ana, California, federal prosecutors asked Judge Andrew Guilford to dismiss all criminal c
- Oncobiologics Changes Name to Outlook Therapeutics; Announces Next Steps for ONS-5010 Clinical Strategyhttps://modernod.com/news/oncobiologics-changes-name-to-outlook-therapeutics-announces-next-steps-for-ons-5010-clinical-strategy/2476161/Oncobiologics announced several key corporate events that enhance the company’s ability to advance the development of its lead product candidate, ONS-5010, a proprietary ophthalmic bevacizumab product candidate for the treatment of wet age related macular degeneration (AMD). These events are in c